×
About 13,306 results

ALLMedicine™ Myelodysplastic Syndromes Center

Research & Reviews  6,329 results

Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes.
https://doi.org/10.1002/cyto.a.24360
Cytometry. Part A : the Journal of the International Soci... Duetz C, Van Gassen S et. al.

May 4th, 2021 - The diagnostic work-up of patients suspected for myelodysplastic syndromes is challenging and mainly relies on bone marrow morphology and cytogenetics. In this study, we developed and prospectively validated a fully computational tool for flow cyt...

Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
https://doi.org/10.1080/21645515.2021.1898307
Human Vaccines & Immunotherapeutics; Linder K, Lulla P

May 4th, 2021 - Patients with Myelodysplastic syndromes (MDS) have few therapy options for sustainable responses in the frontline setting, and even less after hypomethylating agent (HMA) failure in relapsed and refractory setting. The only potential cure is an al...

Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are a...
https://doi.org/10.1080/10428194.2021.1919663
Leukemia & Lymphoma; Wang N, Yuan L et. al.

Apr 27th, 2021 - Double minute chromosomes (DMs) are rare in hematologic malignancies. We presented the cytogenetic characteristics and clinical features of the largest single-center cohort of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patient...

Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitati...
https://doi.org/10.1136/bmjspcare-2020-002865
BMJ Supportive & Palliative Care; Desai AV, Klimek VM et. al.

Apr 27th, 2021 - Evidence-based guidelines call for integration of palliative care within oncology from diagnosis. Misperceptions about palliative care have impeded implementation. Prior research has not examined perceptions about 'palliative care' versus 'support...

Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
https://doi.org/10.1182/bloodadvances.2020002929
Blood Advances; Patel AA, Cahill K et. al.

Apr 27th, 2021 - Since the US Food and Drug Administration (FDA) approvals of parenteral decitabine and azacitidine, DNA methyltransferase inhibitors, otherwise referred to as DNA hypomethylating agents (HMAs), have been a mainstay in the treatment of higher-risk ...

see more →

Guidelines  31 results

Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment a...
https://doi.org/10.1016/j.annonc.2020.11.002
Annals of Oncology : Official Journal of the European Soc... Fenaux P, Haase D et. al.

Nov 22nd, 2020 - Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†☆.|2020|Fenaux P,Haase D,Santini V,Sanz GF,Platzbecker U,|diagnosis,epidemiology,therapy,

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

Hematology Quality Metrics
http://www.hematology.org/Clinicians/Guidelines-Quality/503.aspx
Allen, S.

Feb 20th, 2018 - These clinical performance measures are designed for individual quality improvement. Some of the measures may also be appropriate for accountability if appropriate sample sizes and implementation rules are achieved.

Myelodysplastic Syndromes, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2017.0007
Journal of the National Comprehensive Cancer Network : JN... Greenberg PL, Stone RM et. al.

Jan 3rd, 2017 - The myelodysplastic syndromes (MDS) comprise a heterogenous group of myeloid disorders with a highly variable disease course. Diagnostic criteria to better stratify patients with MDS continue to evolve, based on morphology, cytogenetics, and the p...

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from...
http://www.bloodjournal.org/content/122/17/2943
Malcovati, L.,et al.

Oct 23rd, 2013 - Within the myelodysplastic syndrome (MDS) work package of the European LeukemiaNet, an Expert Panel was selected according to the framework elements of the National Institutes of Health Consensus Development Program. A systematic review of the lit.

see more →

Drugs  59 results see all →

Clinicaltrials.gov  6,589 results

Computational flow cytometry as a diagnostic tool in suspected-myelodysplastic syndromes.
https://doi.org/10.1002/cyto.a.24360
Cytometry. Part A : the Journal of the International Soci... Duetz C, Van Gassen S et. al.

May 4th, 2021 - The diagnostic work-up of patients suspected for myelodysplastic syndromes is challenging and mainly relies on bone marrow morphology and cytogenetics. In this study, we developed and prospectively validated a fully computational tool for flow cyt...

Myelodysplastic syndrome and immunotherapy novel to next in-line treatments.
https://doi.org/10.1080/21645515.2021.1898307
Human Vaccines & Immunotherapeutics; Linder K, Lulla P

May 4th, 2021 - Patients with Myelodysplastic syndromes (MDS) have few therapy options for sustainable responses in the frontline setting, and even less after hypomethylating agent (HMA) failure in relapsed and refractory setting. The only potential cure is an al...

Double minute chromosomes in acute myeloid leukemia and myelodysplastic syndromes are a...
https://doi.org/10.1080/10428194.2021.1919663
Leukemia & Lymphoma; Wang N, Yuan L et. al.

Apr 27th, 2021 - Double minute chromosomes (DMs) are rare in hematologic malignancies. We presented the cytogenetic characteristics and clinical features of the largest single-center cohort of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) patient...

Palliative Medicine in Myelodysplastic Syndromes: Patients and Caregivers - A Qualitati...
https://doi.org/10.1136/bmjspcare-2020-002865
BMJ Supportive & Palliative Care; Desai AV, Klimek VM et. al.

Apr 27th, 2021 - Evidence-based guidelines call for integration of palliative care within oncology from diagnosis. Misperceptions about palliative care have impeded implementation. Prior research has not examined perceptions about 'palliative care' versus 'support...

Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies.
https://doi.org/10.1182/bloodadvances.2020002929
Blood Advances; Patel AA, Cahill K et. al.

Apr 27th, 2021 - Since the US Food and Drug Administration (FDA) approvals of parenteral decitabine and azacitidine, DNA methyltransferase inhibitors, otherwise referred to as DNA hypomethylating agents (HMAs), have been a mainstay in the treatment of higher-risk ...

see more →

News  289 results

Whole-Genome Sequencing Emerging for Routine Cancer Care
https://www.medscape.com/viewarticle/947261

Mar 10th, 2021 - Almost 20 years after the human genome was first mapped, whole-genome sequencing might finally be ready to enter routine cancer care. Researchers at Washington University in St. Louis, St. Louis, Missouri, are commercializing an automated sequenci...

Myelodysplastic Syndromes Clinical Practice Guidelines (ESMO, 2021)
https://reference.medscape.com/viewarticle/944879

Feb 2nd, 2021 - Guidelines on the diagnosis and treatment of myelodysplastic syndromes were published in November 2020 by the European Society of Medical Oncology.[1] The diagnosis of myelodysplastic syndromes (MDS) is based on the blood count, the marrow aspirat...

FDA Approves Oral Therapy for Myelodysplastic Syndromes, CMML
https://www.medscape.com/viewarticle/933602

Jul 7th, 2020 - The Food and Drug Administration has approved Inqovi (decitabine and cedazuridine tablets, Astex Pharmaceuticals) to treat adults with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML). The agency's action gives physicians ...

Considerable Variation Exists in Receipt of Complete Diagnostic Evaluations for Myelodysplastic Syndromes Among Medicare Patients
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200129/full/

May 12th, 2020 - A substantial proportion of Medicare patients with myelodysplastic syndromes (MDS) do not undergo a complete diagnostic evaluation (CDE), including a bone marrow biopsy, to confirm their disease (Abstract 7555).

First Advance in MDS for Decade: Luspatercept for Anemia
https://www.medscape.com/viewarticle/928198

Apr 5th, 2020 - The US Food and Drug Administration (FDA) has approved luspatercept (Reblozyl, Bristol-Myers Squibb/Acceleron) for the treatment of anemia in patients with myelodysplastic syndromes (MDS). The green light represents the first treatment advancement...

see more →

Patient Education  9 results see all →